Dr. Isa Odidi reports

INTELLIPHARMACEUTICS REPORTS DIRECTOR ELECTION RESULTS

The five nominees, each of whom was an incumbent director of IntelliPharmaCeutics International Inc., identified in the management information circular dated Aug. 1, 2023, were elected as directors of the company at the annual meeting of shareholders of the company held today. The voting results, as set out in the scrutineer's report for the meeting, are set out herein.

        VOTING RESULTS FOR DIRECTORS

Name of nominee   Votes for   Votes withheld
                                      
Dr. Isa Odidi     3,825,956            9,248         
                       99.8%            0.24%         
Dr. Amina Odidi   3,825,969            9,235         
                       99.8%            0.24%         
Bahadur Madhani   3,806,196           29,008        
                       99.2%            0.76%         
Norman Betts      3,827,649            7,555         
                       99.8%            0.20%         
Shawn Graham      3,827,637            7,567         
                       99.8%            0.20%         

All other resolutions tabled for consideration at the meeting, as set out in the circular, were also approved by shareholders of the company. See the company's report on voting results filed under the company's profile on SEDAR+ for additional details.

About IntelliPharmaCeutics International Inc.

IntelliPharmaCeutics is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals.

IntelliPharmaCeutics has developed several drug delivery systems based on this technology platform, with a pipeline of products (some of which have received Food and Drug Administration approval) in various stages of development. The company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the company's abuse-deterrent oxycodone hydrochloride extended-release formulation (oxycodone ER) based on its proprietary nPODDDS novel point-of-divergence drug delivery system (for which an NDA has been filed with the FDA) and regabatin XR (pregabalin extended-release capsules).